Selexis CSO to Speak at the Irvine Scientific Exhibit at BPI 2012

Share Article

Dr. Pierre-Alain Girod Will Present Data on Achieving High Yields with Difficult-to-Express Proteins Using the Selexis CHO-M Cell Line Combined with an Optimized Media

News Image

Pierre-Allain Girod, Ph.D., Selexis Chief Scientific Officer

Selexis will present data on achieving high yields with the Selexis CHO-M cell line combined with an optimized media.

Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today the Company’s CSO, Pierre-Alain Gerod, Ph.D., will present “High Performance CHO Cell Line Development Platform for Enhanced Production of Recombinant Proteins Including Difficult to Express Proteins” at the Irvine Scientific Exhibit on Wednesday, October 10 at 3:30 PM. The Irvine Scientific presentations are part of the BioProcess International Conference being held October 8-12, 2012 in Providence, Rhode Island at the Rhode Island Convention Center.

Presentation Abstract:
From discovery to manufacturing, successful biologics development requires robust expression systems. For most protein therapeutics, the manufacturing system of choice is Chinese hamster ovary (CHO) cells. For the past 10 years, Selexis has developed patented technology, proprietary CHO-M cell lines and scale-up processes to produce CHO manufacturing cell lines that routinely achieve expression levels of 1-5 g/L. However, even with these technologies, certain classes of proteins, such as blood clotting factors and/or membrane proteins (GPCRs and ion channels) can be difficult to express. Selexis will present data on achieving high yields with the Selexis CHO-M cell line combined with an optimized media.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. .

For more information:

About Irvine Scientific
Irvine Scientific, a member of JX Holdings group, is a worldwide leader in the design, manufacture and distribution of medical devices, including Industrial Cell Culture, Cytogenetic, Assisted Reproductive Technology (ART) and Specialty Media products. Irvine Scientific is a worldwide media provider that is regulated and adheres to both ISO and FDA regulations with dual manufacturing facilities in California, USA and Tokyo, Japan. Irvine Scientific is a large scale producer of advanced quality cell culture media for the industrial bioprocess, medical, and diagnostic markets. The company’s extensive experience in the design of culture media, compliance with ISO and FDA regulations for class II / III medical devices, industrial scale manufacturing capacity, provides its customers with unique capabilities and support. Irvine Scientific delivers products worldwide to biopharmaceutical industry, research and medical laboratory communities.

For more information:

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Robert Meister
Selexis SA
(602) 953-1716
Email >

Robert Meister
Follow us on
Visit website

Media